Skip to main content

Clinical Trial News & Results

This section provides information about recently completed clinical trials. If you cannot find information about a particular clinical trial, you should note that results may not be available even after the trial ends. Some trials end before completion and results are never published.

Positive Results from Phase 3 BouNDless Trial of Investigational ND0612 in People with Parkinson's Disease Experiencing Motor Fluctuation

JERSEY CITY, N.J., March 18, 2024. Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the publication of results in The Lancet Neurology from the...

Repurposed Drug Fenoprofen Shows Promise Against Endometriosis-Related Pain in Animal Model

March 18, 2024 -- Fenoprofen, a nonsteroidal anti-inflammatory drug (NSAID), successfully alleviated pain and inflammation in a rodent model of endometriosis...

myTomorrows Partners with The ALS Association to Support ALS Patients in Accessing Clinical Trials

NEW YORK, March 14, 2024. myTomorrows today announced a new partnership with the ALS Association, the U.S.-based nonprofit organization fighting ALS on every...

Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS

FOSTER CITY, Calif.--(BUSINESS WIRE) March 14, 2024 -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing...

Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes

LEXINGTON, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company...

Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder

TORONTO--(BUSINESS WIRE) March 13, 2024 --Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage...

FDA Revises Letter of Authorization for the Emergency Use Authorization for Paxlovid

Update: March 13, 2024 -- EUA-labeled Paxlovid is no longer authorized for emergency use, regardless of the labeled or extended expiration date. For both...

PureTech Receives Orphan Drug Designation for LYT-200 in Acute Myeloid Leukemia

13 March 2024 -- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing...

Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)

LONDON--(BUSINESS WIRE) March 13, 2024 -- Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and...

Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia

OSAKA, Japan, and CAMBRIDGE, Massachusetts, March 13, 2024 – Takeda (TSE:4502/NYSE:TAK) today announced positive topline results from a Phase 2...

Delta-8-THC Use Reported by 11% of 12th Graders in 2023

March 12, 2024 -- Use of the psychoactive cannabis product is higher in states without existing delta-8 regulations or cannabis legalization, NIH-funded study...

NIH Opens Long COVID Trials to Evaluate Treatments for Autonomic Nervous System Dysfunction

March 12, 2024 -- Part of NIH’s RECOVER Initiative, trials will test at least three treatments for symptoms such as fast heart rate, dizziness and...

EmpowerPharm Awaits Phase II Clinical Trial On Ground Breaking Cannabidiol Treatment To Manage Social Anxiety Disorder

Burlington, ON March 11, 2024 – EmpowerPharm Inc. is delighted to announce that the final participant has completed their treatment in the Phase II...

Viatris and Mapi Pharma Statement Regarding New Drug Application for GA Depot

March 11, 2024 -- Viatris Inc. has been informed that Mapi Pharma Ltd. has received a Complete Response Letter (CRL) regarding the New Drug Application (NDA)...

Terns Pharmaceuticals Announces Orphan Drug Designation Granted To TERN-701 For The Treatment Of Chronic Myeloid Leukemia

FOSTER CITY, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a...

More Than Two-Thirds of People with Atopic Dermatitis and Skin of Color Experienced Skin Improvement in a First-of-its-Kind Lebrikizumab Study

INDIANAPOLIS, March 10, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced results from a first-of-its-kind study of lebrikizumab specifically...

Regor Initiates Phase 2 Study of Oral Once-daily GLP-1 Agonist RGT-075 for the Treatment of Obesity

CAMBRIDGE, Mass., March 9, 2024. Regor Therapeutics Group ("Regor"), a clinical-stage global biopharmaceutical company powered by a cutting-edge drug discovery...

New Data Shows JNJ-2113, the First and Only Investigational Targeted Oral Peptide, Maintained Skin Clearance in Moderate-to-Severe Plaque Psoriasis Through One Year

SAN DIEGO (March 9, 2024) – Johnson & Johnson today announced the first data from FRONTIER 2, the long-term extension of the Phase 2b FRONTIER 1...

U.S. Food and Drug Administration to Convene Advisory Committee Meeting to Discuss the TRAILBLAZER-ALZ 2 Study of Donanemab

INDIANAPOLIS, March 8, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) expects to...

Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS

CAMBRIDGE, Mass.--(BUSINESS WIRE) March 08, 2024 -- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today...

View older articles

Clinical trial results archive

2024
January, February, March
2023
January, February, March, April, May, June, July, August, September, October, November, December
2022
January, February, March, April, May, June, July, August, September, October, November, December
2021
January, February, March, April, May, June, July, August, September, October, November, December
2020
January, February, March, April, May, June, July, August, September, October, November, December
2019
January, February, March, April, May, June, July, August, September, October, November, December
2018
January, February, March, April, May, June, July, August, September, October, November, December
2017
May, June, July, August, September, October, November, December
2016
October

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.